ipilimumab,nivolumab
bms
['ipi/', 'nivo']
hey make sure the new gi onc doc has a big interest in immunotherapy. tough to argue neoadjuvant ipi/nivo shouldn t be soc in dmmr colorectal. if only that was more than 5% of the patients. #sitc2022 